Exploring the Metabolism of (+)-[(18)F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study †

Documenti analoghi

• LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[18F]Flubatine—A Positron Emission Tomography Radioligand for Imaging α4β2 Nicotinic Acetylcholine Receptors
  di: Friedrich-Alexander Ludwig, et al.
  Pubblicazione: (2016-09-01)
• LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[(18)F]Flubatine—A Positron Emission Tomography Radioligand for Imaging α4β2 Nicotinic Acetylcholine Receptors
  di: Ludwig, Friedrich-Alexander, et al.
  Pubblicazione: (2016)
• Radiation dosimetry of the α(4)β(2) nicotinic receptor ligand (+)-[(18)F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results
  di: Kranz, Mathias, et al.
  Pubblicazione: (2016)
• (+)-[(18)F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls
  di: Tiepolt, Solveig, et al.
  Pubblicazione: (2020)
• Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(−)-[(18)F]Fluspidine in Glioblastoma
  di: Toussaint, Magali, et al.
  Pubblicazione: (2020)